277 related articles for article (PubMed ID: 29089584)
1. ACVR2B/Fc counteracts chemotherapy-induced loss of muscle and bone mass.
Barreto R; Kitase Y; Matsumoto T; Pin F; Colston KC; Couch KE; O'Connell TM; Couch ME; Bonewald LF; Bonetto A
Sci Rep; 2017 Oct; 7(1):14470. PubMed ID: 29089584
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy-related cachexia is associated with mitochondrial depletion and the activation of ERK1/2 and p38 MAPKs.
Barreto R; Waning DL; Gao H; Liu Y; Zimmers TA; Bonetto A
Oncotarget; 2016 Jul; 7(28):43442-43460. PubMed ID: 27259276
[TBL] [Abstract][Full Text] [Related]
3. Treatment with soluble activin type IIB-receptor improves bone mass and strength in a mouse model of Duchenne muscular dystrophy.
Puolakkainen T; Ma H; Kainulainen H; Pasternack A; Rantalainen T; Ritvos O; Heikinheimo K; Hulmi JJ; Kiviranta R
BMC Musculoskelet Disord; 2017 Jan; 18(1):20. PubMed ID: 28103859
[TBL] [Abstract][Full Text] [Related]
4. ACVR2B antagonism as a countermeasure to multi-organ perturbations in metastatic colorectal cancer cachexia.
Huot JR; Pin F; Narasimhan A; Novinger LJ; Keith AS; Zimmers TA; Willis MS; Bonetto A
J Cachexia Sarcopenia Muscle; 2020 Dec; 11(6):1779-1798. PubMed ID: 33200567
[TBL] [Abstract][Full Text] [Related]
5. Cachexia induced by cancer and chemotherapy yield distinct perturbations to energy metabolism.
Pin F; Barreto R; Couch ME; Bonetto A; O'Connell TM
J Cachexia Sarcopenia Muscle; 2019 Feb; 10(1):140-154. PubMed ID: 30680954
[TBL] [Abstract][Full Text] [Related]
6. Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia.
Benny Klimek ME; Aydogdu T; Link MJ; Pons M; Koniaris LG; Zimmers TA
Biochem Biophys Res Commun; 2010 Jan; 391(3):1548-54. PubMed ID: 20036643
[TBL] [Abstract][Full Text] [Related]
7. Treatment with Soluble Activin Receptor Type IIB Alters Metabolic Response in Chemotherapy-Induced Cachexia.
O'Connell TM; Pin F; Couch ME; Bonetto A
Cancers (Basel); 2019 Aug; 11(9):. PubMed ID: 31438622
[TBL] [Abstract][Full Text] [Related]
8. Prevention of chemotherapy-induced cachexia by ACVR2B ligand blocking has different effects on heart and skeletal muscle.
Hulmi JJ; Nissinen TA; Räsänen M; Degerman J; Lautaoja JH; Hemanthakumar KA; Backman JT; Ritvos O; Silvennoinen M; Kivelä R
J Cachexia Sarcopenia Muscle; 2018 Apr; 9(2):417-432. PubMed ID: 29230965
[TBL] [Abstract][Full Text] [Related]
9. The systemic activin response to pancreatic cancer: implications for effective cancer cachexia therapy.
Zhong X; Pons M; Poirier C; Jiang Y; Liu J; Sandusky GE; Shahda S; Nakeeb A; Schmidt CM; House MG; Ceppa EP; Zyromski NJ; Liu Y; Jiang G; Couch ME; Koniaris LG; Zimmers TA
J Cachexia Sarcopenia Muscle; 2019 Oct; 10(5):1083-1101. PubMed ID: 31286691
[TBL] [Abstract][Full Text] [Related]
10. Activin receptor type 2A (ACVR2A) functions directly in osteoblasts as a negative regulator of bone mass.
Goh BC; Singhal V; Herrera AJ; Tomlinson RE; Kim S; Faugere MC; Germain-Lee EL; Clemens TL; Lee SJ; DiGirolamo DJ
J Biol Chem; 2017 Aug; 292(33):13809-13822. PubMed ID: 28659341
[TBL] [Abstract][Full Text] [Related]
11. A myostatin and activin decoy receptor enhances bone formation in mice.
Bialek P; Parkington J; Li X; Gavin D; Wallace C; Zhang J; Root A; Yan G; Warner L; Seeherman HJ; Yaworsky PJ
Bone; 2014 Mar; 60():162-71. PubMed ID: 24333131
[TBL] [Abstract][Full Text] [Related]
12. [Different Types of Low-frequency Electromagnetic Fields Resist Bone Loss Caused by Weightlessness].
Li WY; Tian YH; Gao YH; Zhu BY; Xi HR; Chen KM
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2019 Feb; 41(1):11-20. PubMed ID: 30837037
[TBL] [Abstract][Full Text] [Related]
13. Clodronate prevents osteopenia and loss of trabecular connectivity in estrogen-deficient rats.
Kippo K; Hannuniemi R; Isaksson P; Laurén L; Osterman T; Peng Z; Tuukkanen J; Kuurtamo P; Väänänen HK; Sellman R
J Bone Miner Res; 1998 Feb; 13(2):287-96. PubMed ID: 9495523
[TBL] [Abstract][Full Text] [Related]
14. Muscle and serum metabolomes are dysregulated in colon-26 tumor-bearing mice despite amelioration of cachexia with activin receptor type 2B ligand blockade.
Lautaoja JH; Lalowski M; Nissinen TA; Hentilä J; Shi Y; Ritvos O; Cheng S; Hulmi JJ
Am J Physiol Endocrinol Metab; 2019 May; 316(5):E852-E865. PubMed ID: 30860875
[TBL] [Abstract][Full Text] [Related]
15. A soluble activin receptor type IIB does not improve blood glucose in streptozotocin-treated mice.
Wang Q; Guo T; Portas J; McPherron AC
Int J Biol Sci; 2015; 11(2):199-208. PubMed ID: 25561902
[TBL] [Abstract][Full Text] [Related]
16. Systemic blockade of ACVR2B ligands attenuates muscle wasting in ischemic heart failure without compromising cardiac function.
Szabó Z; Vainio L; Lin R; Swan J; Hulmi JJ; Rahtu-Korpela L; Serpi R; Laitinen M; Pasternack A; Ritvos O; Kerkelä R; Magga J
FASEB J; 2020 Aug; 34(8):9911-9924. PubMed ID: 32427381
[TBL] [Abstract][Full Text] [Related]
17. Treating cachexia using soluble ACVR2B improves survival, alters mTOR localization, and attenuates liver and spleen responses.
Nissinen TA; Hentilä J; Penna F; Lampinen A; Lautaoja JH; Fachada V; Holopainen T; Ritvos O; Kivelä R; Hulmi JJ
J Cachexia Sarcopenia Muscle; 2018 Jun; 9(3):514-529. PubMed ID: 29722201
[TBL] [Abstract][Full Text] [Related]
18. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial.
Xu RH; Muro K; Morita S; Iwasa S; Han SW; Wang W; Kotaka M; Nakamura M; Ahn JB; Deng YH; Kato T; Cho SH; Ba Y; Matsuoka H; Lee KW; Zhang T; Yamada Y; Sakamoto J; Park YS; Kim TW
Lancet Oncol; 2018 May; 19(5):660-671. PubMed ID: 29555258
[TBL] [Abstract][Full Text] [Related]
19. Of mice, rats and men: trabecular bone architecture in mammals scales to body mass with negative allometry.
Barak MM; Lieberman DE; Hublin JJ
J Struct Biol; 2013 Aug; 183(2):123-31. PubMed ID: 23639903
[TBL] [Abstract][Full Text] [Related]
20. Bisphosphonate Treatment Ameliorates Chemotherapy-Induced Bone and Muscle Abnormalities in Young Mice.
Essex AL; Pin F; Huot JR; Bonewald LF; Plotkin LI; Bonetto A
Front Endocrinol (Lausanne); 2019; 10():809. PubMed ID: 31803146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
